Literature DB >> 19471579

Should we modify the current FIGO staging system for stage IIIC ovarian cancer?

Hee-Sug Ryu1.   

Abstract

Entities:  

Year:  2008        PMID： 19471579      PMCID： PMC2676476          DOI： 10.3802/jgo.2008.19.4.207

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN： 2005-0380            Impact factor:   4.401


× No keyword cloud information.
  7 in total

Review 1.  Significance of lymph node sampling in epithelial carcinoma of the ovary.

Authors:  F Carnino; G Fuda; G Ciccone; L Iskra; E Guercio; D Dadone; P F Conte
Journal:  Gynecol Oncol       Date:  1997-06       Impact factor: 5.482

2.  Survival of ovarian carcinoma with or without lymph node metastasis.

Authors:  S S Chen
Journal:  Gynecol Oncol       Date:  1987-07       Impact factor: 5.482

3.  Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary.

Authors:  S S Chen; L Lee
Journal:  Gynecol Oncol       Date:  1983-08       Impact factor: 5.482

4.  Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients.

Authors:  T Onda; H Yoshikawa; T Yasugi; M Mishima; S Nakagawa; M Yamada; K Matsumoto; Y Taketani
Journal:  Cancer       Date:  1998-10-15       Impact factor: 6.860

5.  Surgical staging of carcinoma of the ovaries.

Authors:  H J Buchsbaum; M F Brady; G Delgado; A Miller; W J Hoskins; A Manetta; G Sutton
Journal:  Surg Gynecol Obstet       Date:  1989-09

6.  Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.

Authors:  Su-Jin Baek; Jeong-Yeol Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

7.  Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Authors:  Mehee Choi; Clifton D Fuller; Charles R Thomas; Samuel J Wang
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.